Nanoparticle-mediated drug delivery for the treatment of cardiovascular diseases
Cardiovascular diseases (CVDs) are one of the foremost causes of high morbidity and
mortality globally. Preventive, diagnostic, and treatment measures available for CVDs are …
mortality globally. Preventive, diagnostic, and treatment measures available for CVDs are …
Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents
Platelets are central to inflammation-related manifestations of cardiovascular diseases
(CVD) such as atherosclerosis. Platelet-activating factor (PAF), thrombin, thromboxane A 2 …
(CVD) such as atherosclerosis. Platelet-activating factor (PAF), thrombin, thromboxane A 2 …
Thrombotic regulation from the endothelial cell perspectives
M Wang, H Hao, NJ Leeper, L Zhu - … , thrombosis, and vascular …, 2018 - Am Heart Assoc
Wang et al Endothelium in Thrombosis e91 endothelial TF may be enhanced in
pathophysiological conditions, 16, 17 and ECs were found to be able to secret …
pathophysiological conditions, 16, 17 and ECs were found to be able to secret …
Nanoparticle therapy for vascular diseases
AM Flores, J Ye, KU Jarr… - … , and vascular biology, 2019 - Am Heart Assoc
Nanoparticles promise to advance strategies to treat vascular disease. Since being
harnessed by the cancer field to deliver safer and more effective chemotherapeutics …
harnessed by the cancer field to deliver safer and more effective chemotherapeutics …
D-amino acids and D-amino acid-containing peptides: potential disease biomarkers and therapeutic targets?
M Abdulbagi, L Wang, O Siddig, B Di, B Li - Biomolecules, 2021 - mdpi.com
In nature, amino acids are found in two forms, L and D enantiomers, except for glycine which
does not have a chiral center. The change of one form to the other will lead to a change in …
does not have a chiral center. The change of one form to the other will lead to a change in …
Biomimetic fibrin-targeted and H2O2-responsive nanocarriers for thrombus therapy
Thrombosis is a principle cause of various life-threatening cardiovascular diseases.
However, current antithrombotic treatments using drugs only offer limited efficacy due to …
However, current antithrombotic treatments using drugs only offer limited efficacy due to …
[HTML][HTML] Recent advances in the development of theranostic nanoparticles for cardiovascular diseases
Cardiovascular disease (CVD) is the leading cause of death worldwide. CVD includes a
group of disorders of the heart and blood vessels such as myocardial infarction, ischemic …
group of disorders of the heart and blood vessels such as myocardial infarction, ischemic …
Thrombin, a mediator of coagulation, inflammation, and neurotoxicity at the neurovascular interface: implications for Alzheimer's disease
J Iannucci, W Renehan, P Grammas - Frontiers in neuroscience, 2020 - frontiersin.org
The societal burden of Alzheimer's disease (AD) is staggering, with current estimates
suggesting that 50 million people world-wide have AD. Identification of new therapeutic …
suggesting that 50 million people world-wide have AD. Identification of new therapeutic …
Theranostic nanomedicines for the treatment of cardiovascular and related diseases: current strategies and future perspectives
Cardiovascular and related diseases (CVRDs) are among the most prevalent chronic
diseases in the 21st century, with a high mortality rate. This review summarizes the various …
diseases in the 21st century, with a high mortality rate. This review summarizes the various …
Role of thrombin in the pathogenesis of atherosclerosis
N Jaberi, A Soleimani, M Pashirzad… - Journal of Cellular …, 2019 - Wiley Online Library
Atherosclerosis is an arterial disease associated with inflammation. Thrombin is a
procoagulant and proinflammatory serine protease that contributes to the pathology of …
procoagulant and proinflammatory serine protease that contributes to the pathology of …